GSK1059615   Click here for help

GtoPdb Ligand ID: 9826

Compound class: Synthetic organic
Comment: GSK1059615 is a PI3K and mTOR dual inhibitor [1]. Some data on this compound is nested in a paper characterising GSK2126458 that we have as Omipalisib. GSK1059615 was later reported to inhibited survival and proliferation of established (SCC-9, SQ20B and A253 lines) and primary human HNSCC cells, possibly the latter via programmed necrosis pathway [2] . However,a Phase 1 dose-escalation study against solid tumors or lymphoma was terminated prematurely (July 2017) due to lack of sufficient exposure.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 2
Topological polar surface area 97.25
Molecular weight 333.06
XLogP 2.26
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES O=C1NC(=O)C(=Cc2ccc3c(c2)c(ccn3)c2ccncc2)S1
Isomeric SMILES O=C1NC(=O)/C(=C/c2ccc3c(c2)c(ccn3)c2ccncc2)/S1
InChI InChI=1S/C18H11N3O2S/c22-17-16(24-18(23)21-17)10-11-1-2-15-14(9-11)13(5-8-20-15)12-3-6-19-7-4-12/h1-10H,(H,21,22,23)/b16-10-
No information available.
Summary of Clinical Use Click here for help
GSK1059615 had a Phase 1 trial for solid tumors or lymphoma (NCT00695448) but was terminated prematurely due to lack of sufficient exposure following single- and repeat-dosing.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT00695448 Phase I Open-Label, Dose-Escalation Study of GSK1059615 in Patients With Solid Tumors or Lymphoma Phase 1 Interventional GlaxoSmithKline